Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deuremidevir Hydrobromide in Hospitalized Infants with RSV
NCT06206720Phase 2Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Jan 2024
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of deuremidevir in respiratory syncytial virus infection (RSV), sponsored by Vigonvita Life Sciences. Started Jan 2024; status: completed.
02
Drugs
deuremidevir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06206720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06206720.